Organic Active Ingredients TRIZ Cases

siRNAs targeting sFLT1 mRNA lower circulating protein levels, replacing costly apheresis infrastructure with targeted biological therapy.

Quinacrine targets RNA G-quadruplexes to suppress viral proliferation while achieving effective lung distribution.

Substituted bicyclic dihydropyrimidinones resolve metabolic stability and systemic exposure bottlenecks in neutrophil elastase inhibition.

Lentiviral shRNA delivery silences TUBB2B expression, reducing chemotherapy toxicity while controlling triple-negative breast cancer.

Phosphorothioate-modified cyclic dinucleotides increase STING binding affinity, enabling potent cytokine induction at lower doses across various human alleles.

Lactobacillus paracasei and reuteri composition enhances anticancer efficacy of Gemcitabine chemotherapy.

Fused pyrrole compounds block chymase to reduce tissue damage in allergic and fibrotic diseases.

Replenishing miR-338-3p in thalamic neurons normalizes Drd2 levels to treat schizophrenia positive symptoms without antipsychotic side effects.

Carboxylic acid modification enhances liver targeting and pharmacokinetic properties for CCR2/CCR5 antagonist therapy in nonalcoholic fatty liver disease.

Aptamers bind Ku70 and Ku80 receptors on glioma cells to deliver cytotoxic payloads.

Crystalline PI3K inhibitor salts achieve irreversible alpha enzyme inhibition, resolving the trade-off between stability and manufacturing complexity.

Formula I compounds inhibit APOL1 activity, mitigating focal segmental glomerulosclerosis and non-diabetic kidney disease progression.

Tetrahydroisoquinolinyl derivatives act as positive allosteric modulators to potentiate dopamine D1 receptor activity through distinct binding sites.

PKC-θ inhibitors reduce cancer stem cell proliferation by modulating epithelial-to-mesenchymal transition, addressing drug resistance mechanisms.

Arylimidazolyl isoxazole compounds modulate p300 and CBP activity to overcome resistance in castration-resistant prostate cancer.

Cyanopyrrolidine compounds selectively inhibit UCHL1 and USP30 to treat cancer with reduced toxicity.

Compounds bind the E2-Ub conjugate to disrupt CRL4 catalytic activity, resolving undruggable RING domain screening challenges.

Measuring specific gene expression levels to identify patients likely to benefit from glucocorticoid receptor modulator and chemotherapy combination therapy.

Formula I compounds selectively inhibit tyrosine kinases, resolving the trade-off between broad efficacy and specificity in targeted cancer therapies.

Isolating an aminium salt intermediate during synthesis of 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid.

Optimizing oil concentration in the phospholipid prevents oxidation degradation while maintaining high drug permeation rates.

Kinematic sensors and trained algorithms produce UPDRS-correlated scores, eliminating clinician subjectivity in Parkinson's disease assessment.

Linking anthracycline toxins exclusively to antibody light chain C-termini resolves the trade-off between therapeutic efficacy and in vivo tolerability.

Vinyl acetate polymer prevents maltodextrin-based orodispersible films from hardening over time while maintaining clean mouth sensation.

Modulators inhibit INHBE expression, reducing serum protein levels and treating metabolic syndrome without drug-drug interactions.

Anisomelic acid emulsions restore p53-mediated growth arrest by down-regulating cIAP2, addressing limited survival in advanced cervical cancer.

A 7H-imidazo[1,5-a]pyrazin-8-one compound inhibits PDE9 to increase cGMP levels.

Citrate-coated amorphous calcium phosphate nanoparticles enable targeted remineralization of dentine and enamel surfaces.

Nitro oleic acid microparticles release within a composite scaffold to promote regional angiogenesis and reduce fibrotic response during abdominal wall repair.

Formula I isoindoline compounds lower CHI3L1 and CLU biomarkers in cerebral spinal fluid to address inadequate Alzheimer's disease management.

Piperidine-substituted Mnk inhibitors resolve the trade-off between poor solubility and high potency by blocking eIF4E signaling for cancer treatment.

A pharmaceutical composition containing VCP ATPase inhibitors protects cardiomyocytes from cellular damage.

Administering combined anti-ErbB and anti-MET agents overcomes EGFR inhibitor resistance in non-small cell lung cancer.

Conjugated C5 aptamer reduces geographic atrophy lesion growth and stabilizes visual acuity.

Novel benzyloxypyrazinylcyclopropanecarboxylic acids activate the GPR40 receptor to modulate insulin release.

Replacing dopamine antagonists with phosphatidylserine eliminates extrapyramidal side effects while maintaining stable milk composition and increasing yield.

Deuterated morphinan compounds reduce metabolic liability and adverse side effects by applying kinetic isotope effects at specific molecular positions.

A diagnostic method detects Gi protein-coupled receptor signaling changes in cells to identify compounds for scoliosis treatment.

A cobalt complex catalyst enables selective hydrogenation of unsaturated compounds under ambient conditions.

Modular substitution on the tetrahydro-isoquinoline core enhances H3 receptor binding affinity and selectivity to treat central nervous system disorders.

Combining DII4 antagonists with chemotherapeutic agents blocks tumor blood vessel development, reducing required drug dosages and side effects.

Administering antibodies against Activin B, BMP9, or BMP10 inhibits heterotopic ossification in fibrodysplasia ossificans progressiva.

Composite lipid nanoparticles reduce immunogenicity and off-target effects while maintaining CRISPR editing efficiency.

Enzymatic glycosylation with 3-fluoro sialic acid donors yields stable therapeutic moieties resistant to degradation, overcoming synthesis complexity.

Low water content below 5% and acidifying agents prevent molindone degradation, ensuring stable blood concentrations for CNS disorder treatment.

Trehalose stabilizers preserve high molecular weight hyaluronic acid efficacy by preventing room temperature degradation, eliminating refrigeration needs.

Inositol derivatives block primary calciprotein particle maturation, addressing the lack of approved therapies for vascular calcification.

Novel diamino pyridine derivatives modulate Janus kinase activity through targeted structural substitution.